Alzheimer's Disease
Balanced diet associated with better cognitive function
Maintaining a balanced energy intake through diet was associated with significantly better cognitive function compared with uneven intake patterns, researchers reported in Life Metabolism.
Phase 2 trial of therapeutic for patients with early AD yields positive results
Alzheon Inc. reported statistically significant and clinically relevant results in patients with Alzheimer’s disease following 12 months of treatment with the oral investigational therapeutic ALZ-801 in its phase 2 trial.
Phase 2a cognition, dementia treatment trial underway
CuraSen Therapeutics Inc. announced it has begun dosing patients in a phase 2a clinical trial with CST-2032, an oral therapeutic for treatment of mild cognitive impairment or mild dementia due to either Parkinson’s or Alzheimer’s disease.
NIH awards Cedars-Sinai $8M for AI-based Alzheimer's research
Cedars-Sinai’s department of computational biomedicine has been awarded an $8 million NIH grant to use artificial intelligence methods to identify genetic predictors of Alzheimer's disease.
NIH awards University of Kentucky $20.5 million for Alzheimer’s research
Researchers at the University of Kentucky’s Sanders-Brown Center on Aging have received a $20.5 million grant from the National Institute on Aging to study astrocytes and their role in Alzheimer’s disease and other forms of dementia.
‘This Is Us’ Alzheimer's-based storyline reduced stigma, promoted discussions
An Alzheimer's disease-centered storyline in the primetime television drama series “This Is Us” reduced stigma around dementia and prompted family discussions, researchers reported in the Journal of Health Communications.
Increased risk for COVID-19 infection, death among adults with dementia
Older adults with dementia are at greater risk for SARS-CoV-2 infection and death, highlighting the need for close monitoring of these patients, researchers reported in the Journal for Alzheimer’s Disease.
Alpha Cognition announces positive results from study of AD therapeutic
Alpha Cognition Inc. has announced positive results from a bioequivalence study with Alpha-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s disease.
High BMI negatively associated with dementia in women, low BMI linked with disease in men
Being overweight was negatively associated with the incidence of dementia in women in Germany, while being underweight was linked to dementia in men, researchers reported in the Journal of Alzheimer’s Disease.
Cell stress, mitochondrial dysfunction observed in early Alzheimer's patients
Researchers at Invicro have found evidence supporting cellular stress and bioenergetic abnormalities in patients with early-stage Alzheimer's disease, according to new data published in Science Translational Medicine.